Revenue
0 USD
2026-06-30 · USD
Fundies. English
Maze Therapeutics, Inc.
EDGARAnnual consolidated revenue for 2024: about USD 167.5M, using the latest reported figures.
Latest quarter
Operating cash flow
-15.1 million USD
2026-06-30 · USD
Free cash flow
-15.2 million USD
2026-06-30 · USD
- Cash and cash equivalents
- 203 million USD Source
Exact value
202643000 USD
- Long-term debt including current maturities
- 39 million USD
Exact inputs and evidence
38960000 USD
- Long-term debt including current maturities: 38960000 USD Source
- Shares outstanding
- 55.5 million shares Source
Exact value
55504574 shares
Reported share-count change
26.58% · 11.7 million shares
Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.
Trailing twelve months
The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.
Net income
-134 million USD
2025-07-01 – 2026-06-30
Exact inputs and evidence
Operating cash flow
-107 million USD
2025-07-01 – 2026-06-30
Exact inputs and evidence
- Operating cash flow: -84210000 USD · 2025-01-01 – 2025-09-30 Source
- Operating cash flow: -59568000 USD · 2025-01-01 – 2025-06-30 Source
- Operating cash flow: -111940000 USD · 2025-01-01 – 2025-12-31 Source
- Operating cash flow: -84210000 USD · 2025-01-01 – 2025-09-30 Source
- Operating cash flow: -39113000 USD · 2026-01-01 – 2026-03-31 Source
- Operating cash flow: -54166000 USD · 2026-01-01 – 2026-06-30 Source
- Operating cash flow: -39113000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure
302 thousand USD
2025-07-01 – 2026-06-30
Exact inputs and evidence
- Capital expenditure: 760000 USD · 2025-01-01 – 2025-09-30 Source
- Capital expenditure: 692000 USD · 2025-01-01 – 2025-06-30 Source
- Capital expenditure: 794000 USD · 2025-01-01 – 2025-12-31 Source
- Capital expenditure: 760000 USD · 2025-01-01 – 2025-09-30 Source
- Capital expenditure: 93000 USD · 2026-01-01 – 2026-03-31 Source
- Capital expenditure: 200000 USD · 2026-01-01 – 2026-06-30 Source
- Capital expenditure: 93000 USD · 2026-01-01 – 2026-03-31 Source
Free cash flow
-107 million USD
2025-07-01 – 2026-06-30
Exact inputs and evidence
- Operating cash flow: -84210000 USD · 2025-01-01 – 2025-09-30 Source
- Operating cash flow: -59568000 USD · 2025-01-01 – 2025-06-30 Source
- Operating cash flow: -111940000 USD · 2025-01-01 – 2025-12-31 Source
- Operating cash flow: -84210000 USD · 2025-01-01 – 2025-09-30 Source
- Operating cash flow: -39113000 USD · 2026-01-01 – 2026-03-31 Source
- Operating cash flow: -54166000 USD · 2026-01-01 – 2026-06-30 Source
- Operating cash flow: -39113000 USD · 2026-01-01 – 2026-03-31 Source
- Capital expenditure: 760000 USD · 2025-01-01 – 2025-09-30 Source
- Capital expenditure: 692000 USD · 2025-01-01 – 2025-06-30 Source
- Capital expenditure: 794000 USD · 2025-01-01 – 2025-12-31 Source
- Capital expenditure: 760000 USD · 2025-01-01 – 2025-09-30 Source
- Capital expenditure: 93000 USD · 2026-01-01 – 2026-03-31 Source
- Capital expenditure: 200000 USD · 2026-01-01 – 2026-06-30 Source
- Capital expenditure: 93000 USD · 2026-01-01 – 2026-03-31 Source
Includes later revisions to earlier periods. Annual charts exclude incomplete years.
Latest filing recorded: 2026-10-16.
Financial data available through: 2024-12-31.
Financial coverage is incomplete. Newer filings are recorded, but comparable financial figures for those periods are not available here yet.
Coverage by financial measure
- Revenue: 1 of 11 periods available· newest 2024-12-31
- Operating income: 1 of 11 periods available· newest 2024-12-31
- Net income: 1 of 11 periods available· newest 2024-12-31
- Operating cash flow: 1 of 11 periods available· newest 2024-12-31
- Capital expenditure: 1 of 11 periods available· newest 2024-12-31
- Total assets: 1 of 11 periods available· newest 2024-12-31
- Total liabilities: 1 of 11 periods available· newest 2024-12-31
- Current assets: 1 of 11 periods available· newest 2024-12-31
- Current liabilities: 1 of 11 periods available· newest 2024-12-31
- Cash and cash equivalents: 1 of 11 periods available· newest 2024-12-31
- long term debt: No compatible figures in this window
- Shares outstanding: 1 of 11 periods available· newest 2024-12-31
Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.
What changed year over year
Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.
No unambiguous prior-year comparison is available for the latest reporting period.
Comparable inputs unavailable for: Revenue, Net income, Operating cash flow, Capital expenditure.
Where revenue goes
How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.
2024 2024-01-01 – 2024-12-31
- Revenue USD 167.5 million 100% of revenue
- Operating costs Derived USD 109.91 million 66% of revenue
- Operating income USD 57.59 million 34% of revenue
- Tax, interest and other Derived USD 5.36 million 3.2% of revenue
- Net income USD 52.23 million 31% of revenue
Cash
- Operating cash flow USD 75.95 million 45% of revenue
- Capital expenditure USD 1.15 million 0.7% of revenue
- Free cash flow Derived USD 74.81 million 45% of revenue
Share of revenue by period
- Net income
- Tax, interest and other
- Operating costs
- 2024 31%66%
Values and sources
| Period | Revenue | Operating costs | Operating income | Tax, interest and other | Net income | Free cash flow | Source |
|---|---|---|---|---|---|---|---|
| 2024 2024-01-01 – 2024-12-31 | 167500000 | 109914000 Derived | 57586000 | 5355000 Derived | 52231000 | 74807000 Derived | Source
|
Amounts are exact, in USD.
Growth
Sales over time and how quickly they are changing.
Revenue
Revenue reported for each complete financial period.
USD 167.5M 2024
Values and sources
| Period | Series | Value(USD) | Source evidence |
|---|---|---|---|
| 2024 | Revenue | 167500000 |
|
Revenue growth
Change in revenue from the same financial period one year earlier.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2024 | Year over year | No prior comparable period |
|
Profit and cash
How much revenue becomes profit, and how much cash operations generate.
Profit margins
Operating income, net income and free cash flow as a share of revenue.
Operating margin 34.4% 2024
Net margin 31.2% 2024
Free cash flow margin 44.7% 2024
- Operating margin
- Net margin
- Free cash flow margin
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2024 | Operating margin | 34.4% |
|
| 2024 | Net margin | 31.2% |
|
| 2024 | Free cash flow margin | 44.7% |
|
Operating cash flow
Cash generated by the company’s normal business operations.
USD 76M 2024
Values and sources
| Period | Series | Value(USD) | Source evidence |
|---|---|---|---|
| 2024 | Operating cash flow | 75954000 |
|
Free cash flow
Operating cash flow minus capital expenditure for the same period and unit.
USD 74.8M 2024
Values and sources
| Period | Series | Value(USD) | Source evidence |
|---|---|---|---|
| 2024 | Free cash flow | 74807000 |
|
Balance sheet
Liabilities and short-term ability to meet obligations at each period end.
Liabilities to assets
Total liabilities as a share of total assets.
18.1% 2024
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2024 | Liabilities / assets | 18.1% |
|
Current assets to current liabilities
Current assets divided by current liabilities.
9.76× 2024
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2024 | Current assets / current liabilities | 9.76× |
|
Cash generation
Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.
| Period | Net income | Operating cash flow | Capital expenditure | Free cash flow |
|---|---|---|---|---|
| 2024 2024-01-01 – 2024-12-31 | USD 52.23 million Exact valueExact value: 52231000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 75.95 million Exact valueExact value: 75954000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 1.15 million Exact valueExact value: 1147000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 74.81 million Calculation and evidence75954000 − 1147000 USD Exact free cash flow: 74807000 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.
Dataset coverage and company identifiers
Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.
11 filings · 537 latest values · 537 originally reported values
Dataset published . Source filing dates and reporting periods are shown separately.
Identifiers: 0001842295, 1842295, MAZE, edgar:1842295
Also known as MAZE THERAPEUTICS, INC., Maze Therapeutics, Inc.